HOME >> MEDICINE >> NEWS
Participation in clinical trials does not appear to affect physician's adherence to guidelines

Physicians who participated in a pharmaceutical-sponsored clinical trial involving asthma medications maintained adherence to treatment guidelines but were more likely to prescribe the sponsor's drugs, according to a study in the June 21 issue of JAMA.

Pharmaceutical companies are frequently involved in clinical trials in general practice, and this may trigger an increase in the use of the sponsoring company's products due to the physicians' experience with these products. This effect may be further strengthened by close physician-company cooperation, which may create physician loyalty toward the company. The effect of participation in company-sponsored studies on drug preferences has not been evaluated in primary care.

Morten Andersen, M.D., Ph.D., of the University of Southern Denmark, Odense, and colleagues investigated the effects of physicians participating in a pharmaceutical company-sponsored clinical trial that was aimed at improving patients' use of asthma medicine. The study compared 10 practices that were conducting the trial on asthma medicine with 165 control (nontrial-conducting) practices in Funen County, Denmark. The study included 5,439 patients treated with asthma drugs from the trial-conducting practices and 59,574 patients from the control practices.

The researchers found that the prevalence of inhaled steroid use among asthma patients increased from 68.5 percent at baseline to 72.9 percent during the second observation year in trial-conducting practices and from 69.1 percent to 73.3 percent in control (nontrial-conducting) practices. There was no impact of participating in the trial on physicians' adherence to international treatment guidelines. Both trial-conducting and control practices had a gradually increased use of the trial sponsor's inhaled corticosteroids, from 74.8 percent to 81.5 percent in trial-conducting practices and from 73.6 percent to 76.6 percent in control practices. Trial-conducting practices were 2
'"/>

Contact: Morten Andersen, M.D., Ph.D.
mandersen@health.sdu.dk
JAMA and Archives Journals
20-Jun-2006


Page: 1 2

Related medicine news :

1. New contracts support clinical trials on antibiotic-resistant, community-acquired staph infections
2. Damon Runyon renews its $2.25 million investment to support young clinical cancer investigators
3. International journal group updates guidelines on registration of clinical trials
4. Urgent need for guidance on mobile phone use in clinical care
5. New prostate cancer clinical guidelines to be released
6. First clinical trial of gene therapy for childhood blindness
7. Acute coronary syndrome therapy improvements linked with fewer deaths and improved clinical outcomes
8. Taking the wraps off drug safety data from clinical trials
9. Preclinical results of Geovaxs AIDS vaccines demonstrate potential to protect against disease
10. 30+ AIDS vaccine clinical trials in 24 countries, research occurring on every continent
11. NIH-funded program co-directed by Mailman School of PH faculty to expedite clinical research process

Post Your Comments:
(Date:5/29/2015)... 29, 2015 Ready to hit the road? ... all drivers to get their vehicles ready. With handicapped vehicles, ... Advanced Driving Systems (ADS) is ready to help drivers get ... for summer road trips. , When planning for the big ... ensure that the trip goes smoothly and they are prepared ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 John A. ... to Cincinnati , The Department of Veterans Affairs (VA) ... Gennaro as the new director of the Cincinnati VA ... care to more than 43,000 unique Veterans annually and ... over 2,000 staff, CVAMC is a two-division campus located ...
(Date:5/29/2015)... May 29, 2015 According to a recent ... 10 full-time workers has a substance abuse problem - the ... than 111,500 adults with full-time jobs, revealed that 9.5% of ... previous year. (1) The National Council on Alcoholism and Drug ... year, and an estimated 70% of the 14.8 million illicit ...
(Date:5/29/2015)... Johnson & Johnson and its ... lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement with a California ... use of the antipsychotic medication. According to court ... third bellwether trial to involve male breast growth ... Pennsylvania’s Philadelphia Court of Common Pleas, where more ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Inspire Nexus, ... created a solution to the question many life coaches ... gain the experience and hours necessary to become a ... pondered this question, but not for long. Inspire Nexus, ... to hire Coaches directly. Coaches who have experience coaching ...
Breaking Medicine News(10 mins):Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 3Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3
(Date:5/29/2015)... 29, 2015  Eli Lilly and Company (NYSE: ... announced that they have entered into a clinical trial ... AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination ... antiangiogenic cancer medicine. The planned study will assess the ... tumors. The Phase I study is expected ...
(Date:5/29/2015)... prostate surgeon and New York Urologist, Dr. David Samadi ... Fusion-Guided Biopsy for detecting aggressive prostate cancer . ... Lenox Hill Hospital is the only center using the revolutionary ... City . We,ve seen tremendous improvement in detecting and ... an MRI makes for a much more accurate diagnosis, especially ...
(Date:5/28/2015)...  Eli Lilly and Company (NYSE: LLY ) announced ... offer for up to $1.6 billion aggregate principal amount of ... notes who tendered, and did not validly withdraw, their notes ... time, on May 27, 2015 (the early tender ... eligible to receive the total consideration. The total consideration for ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
Cached News: